369 related articles for article (PubMed ID: 27364499)
21. Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy.
Mulders PF; Molina A; Marberger M; Saad F; Higano CS; Chi KN; Li J; Kheoh T; Haqq CM; Fizazi K
Eur Urol; 2014 May; 65(5):875-83. PubMed ID: 24099659
[TBL] [Abstract][Full Text] [Related]
22. Exponential rise in prostate-specific antigen (PSA) during anti-androgen withdrawal predicts PSA flare after docetaxel chemotherapy in patients with castration-resistant prostate cancer.
Han KS; Hong SJ
Yonsei Med J; 2015 Mar; 56(2):368-74. PubMed ID: 25683983
[TBL] [Abstract][Full Text] [Related]
23. Oncological Outcome of Docetaxel-Based Chemotherapy for Men with Metastatic Castration-Resistant Prostate Cancer.
Bejrananda T; Pripatnanont C; Tanthanuch M; Karnjanawanichkul W
J Med Assoc Thai; 2016 Dec; 99(12):1315-21. PubMed ID: 29952517
[TBL] [Abstract][Full Text] [Related]
24. Risk Factors for Poor Survival in Metastatic Castration-resistant Prostate Cancer Treated With Cabazitaxel in Japan.
Yasuoka S; Yuasa T; Ogawa M; Komai Y; Numao N; Yamamoto S; Kondo Y; Yonese J
Anticancer Res; 2019 Oct; 39(10):5803-5809. PubMed ID: 31570485
[TBL] [Abstract][Full Text] [Related]
25. An exploratory retrospective multicenter study of prognostic factors in mCRPC patients undergoing enzalutamide treatment: Focus on early PSA decline and kinetics at time of progression.
Miyazawa Y; Sekine Y; Shimizu N; Takezawa Y; Nakamura T; Miyao T; Nakayama H; Kurihara S; Syuto T; Nomura M; Koike H; Matsui H; Shibata Y; Suzuki K
Prostate; 2019 Sep; 79(12):1462-1470. PubMed ID: 31334872
[TBL] [Abstract][Full Text] [Related]
26. PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: Multicenter validation in patients from the Chinese Prostate Cancer Consortium.
Pei X; Wu K; Sun Y; Gao X; Gou X; Xu J; Gao F; He D; Li L;
Urol Oncol; 2020 Jan; 38(1):2.e11-2.e17. PubMed ID: 31672485
[TBL] [Abstract][Full Text] [Related]
27. Matrix metalloproteinase 7, soluble Fas and Fas ligand serum levels for predicting docetaxel resistance and survival in castration-resistant prostate cancer.
Szarvas T; Sevcenco S; Módos O; Keresztes D; Nyirády P; Csizmarik A; Ristl R; Puhr M; Hoffmann MJ; Niedworok C; Hadaschik B; Maj-Hes A; Shariat SF; Kramer G
BJU Int; 2018 Oct; 122(4):695-704. PubMed ID: 29802777
[TBL] [Abstract][Full Text] [Related]
28. No significant impact of patient age and prior treatment profile with docetaxel on the efficacy of cabazitaxel in patient with castration-resistant prostate cancer.
Kosaka T; Hongo H; Watanabe K; Mizuno R; Kikuchi E; Oya M
Cancer Chemother Pharmacol; 2018 Dec; 82(6):1061-1066. PubMed ID: 30283980
[TBL] [Abstract][Full Text] [Related]
29. Rational indication for docetaxel rechallenge in metastatic castration-resistant prostate cancer.
Heck MM; Thalgott M; Retz M; Wolf P; Maurer T; Nawroth R; Hatzichristodoulou G; Gschwend JE; Kübler H
BJU Int; 2012 Dec; 110(11 Pt B):E635-40. PubMed ID: 22889368
[TBL] [Abstract][Full Text] [Related]
30. Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer.
Angelergues A; Maillet D; Fléchon A; Ozgüroglu M; Mercier F; Guillot A; Le Moulec S; Gravis G; Beuzeboc P; Massard C; Fizazi K; de La Motte Rouge T; Delanoy N; Elaidi RT; Oudard S
Eur J Cancer; 2014 Jun; 50(9):1602-9. PubMed ID: 24725337
[TBL] [Abstract][Full Text] [Related]
31. Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from SWOG 0421.
Lara PN; Ely B; Quinn DI; Mack PC; Tangen C; Gertz E; Twardowski PW; Goldkorn A; Hussain M; Vogelzang NJ; Thompson IM; Van Loan MD
J Natl Cancer Inst; 2014 Apr; 106(4):dju013. PubMed ID: 24565955
[TBL] [Abstract][Full Text] [Related]
32. Immunohistochemical staining of ERG and SOX9 as potential biomarkers of docetaxel response in patients with metastatic castration-resistant prostate cancer.
Song W; Kwon GY; Kim JH; Lim JE; Jeon HG; Il Seo S; Jeon SS; Choi HY; Jeong BC; Lee HM
Oncotarget; 2016 Dec; 7(50):83735-83743. PubMed ID: 27863438
[TBL] [Abstract][Full Text] [Related]
33. Changes in fPSA level could discriminate tPSA flare-up from tPSA progression in patients with castration-refractory prostate cancer during the initial phase of docetaxel-based chemotherapy.
Du J; Yang Q; Chen XS; Tian J; Yao X
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1055-61. PubMed ID: 24043138
[TBL] [Abstract][Full Text] [Related]
34. Circulating tumor cells as a biomarker predictive of sensitivity to docetaxel chemotherapy in patients with castration-resistant prostate cancer.
Okegawa T; Itaya N; Hara H; Tambo M; Nutahara K
Anticancer Res; 2014 Nov; 34(11):6705-10. PubMed ID: 25368278
[TBL] [Abstract][Full Text] [Related]
35. External validation of risk classification in patients with docetaxel-treated castration-resistant prostate cancer.
Nakano K; Komatsu K; Kubo T; Natsui S; Nukui A; Kurokawa S; Kobayashi M; Morita T
BMC Urol; 2014 Apr; 14():31. PubMed ID: 24742323
[TBL] [Abstract][Full Text] [Related]
36. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
de Bono JS; Smith MR; Saad F; Rathkopf DE; Mulders PFA; Small EJ; Shore ND; Fizazi K; De Porre P; Kheoh T; Li J; Todd MB; Ryan CJ; Flaig TW
Eur Urol; 2017 Apr; 71(4):656-664. PubMed ID: 27402060
[TBL] [Abstract][Full Text] [Related]
37. Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials.
van Soest RJ; Templeton AJ; Vera-Badillo FE; Mercier F; Sonpavde G; Amir E; Tombal B; Rosenthal M; Eisenberger MA; Tannock IF; de Wit R
Ann Oncol; 2015 Apr; 26(4):743-749. PubMed ID: 25515657
[TBL] [Abstract][Full Text] [Related]
38. Significance of De Ritis (Aspartate Transaminase/Alanine Transaminase) Ratio as a Significant Prognostic But Not Predictive Biomarker in Japanese Patients with Metastatic Castration-resistant Prostate Cancer Treated with Cabazitaxel.
Miyake H; Matsushita Y; Watanabe H; Tamura K; Suzuki T; Motoyama D; Ito T; Sugiyama T; Otsuka A
Anticancer Res; 2018 Jul; 38(7):4179-4185. PubMed ID: 29970547
[TBL] [Abstract][Full Text] [Related]
39. Co-introduction of a steroid with docetaxel chemotherapy for metastatic castration-resistant prostate cancer affects PSA flare.
Shiota M; Yokomizo A; Takeuchi A; Kiyoshima K; Inokuchi J; Tatsugami K; Shiga KI; Koga H; Yamaguchi A; Naito S; Eto M
BJU Int; 2016 Dec; 118(6):880-884. PubMed ID: 26991851
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: implications for prior therapy in clinical trials.
Pond GR; Armstrong AJ; Galsky MD; Wood BA; Leopold L; Sonpavde G
Urol Oncol; 2013 Nov; 31(8):1457-63. PubMed ID: 22552048
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
